期刊文献+

异帕米星治疗呼吸系统感染患者的临床疗效与安全性评价 被引量:2

Evaluation of clinical efficacy and safety of isepamicin
下载PDF
导出
摘要 目的观察并帕米星治疗呼吸系统感染患者的临床疗效及安全性。方法选取呼吸系统感染患者110例,随机分为治疗组和对照组各55例;对照组治疗:在0.9%生理盐水250ml中加入头孢塞肟钠3.0g,静脉滴注,每日两次;治疗组在对照组用药的基础上加入异帕米星,400mg静脉滴注,每日两次;两组疗程均为7~10天,疗程结束后,评价两组的疗效及不良反应。结果治疗组临床疗效和对细菌的消除率均优于对照组(P〈0.05),不良反应发生率两组间差异不显著(P〉0.05)。结论异帕米星临床对呼吸系统感染患者的治疗,疗效可靠,安全性高,具有临床应用价值。 Objective To observe clinical efficacy and safety of iseparaicin. Methods 110 patients with respiratory infections were randomly divided into treatment group (55 cases) and control group (55 cases). Treatment group was treated with isepamicin and cefotaxime sodium. Control group was treated with cefotaxime. Results Clinical efficacy of the treatment group was better than that of the control group. The incidence of adverse reactions was no significant differences. Conclusion Clinical efficacy of isepamicin is reliable and safe.
出处 《西部医学》 2010年第4期654-655,共2页 Medical Journal of West China
关键词 异帕米星 临床疗效 安全性 Isepamicin Clinical efficacy Security
  • 相关文献

参考文献5

二级参考文献39

  • 1朱峰,王尔健,张婴元,吴卫红,吴湜,吴培澄.异帕米星的临床评价60例[J].新药与临床,1993,12(4):194-197. 被引量:2
  • 2孙宏莉,王辉,陈民钧.甲氧西林耐药的金黄色葡萄球菌耐药性及分子流行病学调查[J].中华微生物学和免疫学杂志,2005,25(2):137-141. 被引量:61
  • 3顾金林,顾同进,朱惠莉,沈维敏,郑丽叶,邓伟吾.异帕米星治疗下呼吸道感染[J].新药与临床,1996,15(5):294-296. 被引量:2
  • 4方红,张婴元.氨基糖苷类抗菌新药──异帕米星[J].新药与临床,1996,15(5):299-301. 被引量:9
  • 5高杉 益充.氨基糖甙类抗生素Isepamicin 的一日一回的给药方法(once a day ) [J].化学疗法の领域,1991,7(10):1967-1967.
  • 6松本一彦.HAPA-Bのラットにおおにろ肾毒性试验[J].Chemotherapy,1985,33:47-88.
  • 7腾正孝 齐腾焉.New antimicrobial agents[J].Jpn J Antibiot,1989,42:543-566.
  • 8Vigano A, Principi N. A randomised comparison of isepamicin and amikacin in the treatment of bacterial infections in paediatric patients[J]. J Chemother , 1995,2(Suppl) : 95-101.
  • 9Akiyoshi M, Nakada H,Yano S. Experimental study on ototoxicity of HAPA-B[J]. Otemotherapy , 1985,33:90.
  • 10Endo K. Neuromuscular blocking properties of arbekacin, astromicin, isepamicin and netilmicin in the rabbit[J]. Jpn J Antibiot , 1999,52(8) : 554-561.

共引文献29

同被引文献30

  • 1张芳,李玉敏,王立秋,崔琴.异帕米星对金葡菌的体外抗菌活性分析[J].中国抗生素杂志,2007,32(6):365-366. 被引量:5
  • 2Okubo T, Iyobe S. Antibacterial activities and PK/PD parameters of aminoglycosides against recent clinical isolates of gram-negative rods [J]. Jpn J Antibiot, 2002, 55 (5): 514-523.
  • 3Biswas SK, Kelkar RS. In vitro comparative evaluation of aminoglycosides at a cancer centre [J] .Indian J Cancer, 2002, 39(4): 135-138.
  • 4Fuentes F, Izquierdo J, Martin MM, et al. Postantibiotic and Sub-MIC effects of azithromycin and isepamicin against Staphylococcus aureus and Escherichia coli [J] .Antimicrob Agents Chemother, 1998, 42 (2) : 414-418.
  • 5Magnet S, Blanchard JS. Molecular insights into aminoglycoside action and resistance [J]. Chem Rev, 2005, 105 (2) : 477-498.
  • 6Dubois V, Poirel L, Marie C, et al. Molecular characterization of a novel class 1 integron containing bla (GES- 1) and a fused product of aac3-Ib/aac6'-Ib' gene cassettes in Pseudomonas aeruginosaLJ]. Antimicrob Agents Chemother, 2002, 46 (3): 638-645.
  • 7Yu YS, Zhou H, Yang Q, et al. Widespread occurrence of aminoglycoside resistance due to ArmA methylase in imipenem-resistant Acinetobacter baumannii isolates in China [J]. J Antimicrob Chemother, 2007, 60 (2):454-455.
  • 8Doi Y, Arakawa Y. 16S ribosomal RNA methylation:emerging resistance mechanism against aminoglycosides [J]. Clin Infect Dis, 2007, 45 (1) : 88-94.
  • 9Radwanski E, Batra V, Cayen M, et al. Pharmacokinetics of isepamicin following a single administration by intravenous infusion or intramuscular injection [J]. Antimicrob Agents Chemother, 1997, 41 (8) : 1794-1796.
  • 10Tod M, Padoin C, Petitjean O. Clinical pharmacokinetics and pharmacodynamics of isepamicin [J]. Clin Pharmacokinet, 2000, 38 (3) : 205-223.

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部